589-2A→G) who had been receiving insulin and metreleptin were switched to tirzepatide and were successfully weaned off other therapy.

Tirzepatide, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, represents a novel therapeutic option for both glycemic control and ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.

investigating the dual agonist GLP-1/GIP drug tirzepatide in this Study instead of the GLP-1 agonist semaglutide from human pilot study #1. The DehydraTECH-tirzepatide test articles were compound ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Online pharmacies will now have to employ stricter checks to stop people who are already a healthy weight or have a history ...

Tirzepatide mimics the hormones GLP-1 and GIP, which a person’s stomach produces whenever they eat. These hormones reduce appetite, which can result in weight loss. You must also follow a ...

On December 19, 2024, FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly is tirzepatide’s patentholder and the ...

Mounjaro (tirzepatide) is a prescription drug used ... It’s a type of drug called a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...